Celularity Acquires Rebound, A Placental-derived Allograft Matrix Product, From Sequence LifeScience; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
Celularity has acquired Rebound, a placental-derived allograft matrix product, from Sequence LifeScience. The company expects Rebound sales to significantly contribute to its biomaterial sales in 2024.
October 16, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celularity has acquired Rebound, a placental-derived allograft matrix product, from Sequence LifeScience. The acquisition is expected to boost Celularity's biomaterial sales in 2024.
The acquisition of Rebound is a strategic move by Celularity to enhance its product offerings and revenue streams. The expected contribution to biomaterial sales in 2024 suggests a positive impact on future earnings, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90